Frontline Nivolumab Combination Improves Outcomes in ES-SCLC
The addition of nivolumab to platinum-etoposide chemotherapy improved both progression-free and overall survival in patients with extensive-stage small cell lung cancer (ES-SCLC), according to results from the randomized Phase II ECOG-ACRIN EA5161 trial.